Showing 7531-7540 of 8649 results for "".
- Surface Ophthalmics’ Chronic Dry Eye Study Reaches 50% Enrollment Milestonehttps://modernod.com/news/surface-ophthalmics-chronic-dry-eye-study-reaches-50-enrollment-milestone/2479173/Surface Ophthalmics, Inc. today announced that 50% of patients have been enrolled and randomized in the Phase II clinical trial for its investigational product SURF-100 (mycophenolate sodium and betamethasone sodium phosphate in Klarity vehicle) for the treatment of chronic dry eye disease. Havin
- Verana Health: Study Demonstrates Promise of Real-World Data in Ophthalmic Clinical Developmenthttps://modernod.com/news/verana-health-study-demonstrates-promise-of-real-world-data-in-ophthalmic-clinical-development/2479172/Verana Health unveiled research during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. In a first-of-its kind study, Verana Health demonstrated that it was able to successfully use
- CooperVision Expands Prescription Options for Biofinity XR Toric Contact Lenseshttps://modernod.com/news/coopervision-expands-prescription-options-for-biofinity-xr-toric-contact-lenses/2479170/CooperVision is introducing a broader range of expanded parameters for its Biofinity XR toric lenses. The addition of sphere powers from ±10.50D to ±20.00D nearly doubles the number of available prescription options specific to this lens, making it easier for eye care professionals to fit patient
- Eversight Names Diane Hollingsworth President/CEOhttps://modernod.com/news/eversight-names-diane-hollingsworth-president-ceo/2479171/Eversight announced that Diane Hollingsworth has been named President/CEO of the nonprofit eye bank network, effective immediately. Ms. Hollingsworth has served as interim President/CEO s
- Unity Biotechnology Presents Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseaseshttps://modernod.com/news/unity-biotechnology-presents-data-demonstrating-improvement-in-retinal-vasculature-and-function-in-preclinical-models-of-diabetic-retinopathy-eye-diseases/2479156/Unity Biotechnology announced preclinical data demonstrating that UBX1325, a novel senolytic small molecule inhibitor of Bcl-xL, improves retinal vasculature and is differentiated from anti-VEGF agents in preclinical models. Researchers show that inhibition of retinal Bcl-xL by UBX1325 selectivel
- Ophtec Introduces Precizon Presbyopic Toric IOLhttps://modernod.com/news/ophtec-introduces-precizon-presbyopic-toric-iol/2479159/Ophtec announced the introduction of the Precizon Presbyopic Toric IOL, a spin-off of the Precizon Toric and Precizon Presbyopic. The IOL offers patients the qualities of both models, according to a company news release. The toric is unique because of its TCT (Transitional Conic Toric<
- The Countess of Wessex Praises Work of Sight-Saving Charity Orbis During Pandemichttps://modernod.com/news/the-countess-of-wessex-praises-work-of-sight-saving-charity-orbis-during-pandemic/2479147/On April 28, 2021, Her Royal Highness The Countess of Wessex spoke in support of international eye care charity Orbis, at a virtual event to discuss delivering eye care to those most in need during the COVID-19 outbreak.
- Market Scope: Backlog of 6 Million Cataract Surgeries Will Help Drive IOL Market Through 2026https://modernod.com/news/backlog-of-6-million-cataract-surgeries-will-help-drive-iol-market-through-2026/2479127/Pandemic-impacted 2020 led to a backlog of more than 6 million cataract surgeries globally, as procedures declined 25 percent to 22 million, the lowest number since 2010, mainly due to COVID-related shutdowns in elective surgeries, according to a Market Scope report. The amount of time it
- Eyemate System for Remote Glaucoma Management Obtains FDA Breakthrough Device Designationhttps://modernod.com/news/eyemate-system-for-remote-glaucoma-management-obtains-fda-breakthrough-device-designation/2479126/Implandata Ophthalmic Products announced today that its Eyemate system for digitally enabled remote patient monitoring and management of glaucoma has obtained Breakthrough Device Designation (BDD) from the US FDA. A BDD is only assigned for breakthrough technologies that have the potential to pro
- Hoya Vision Care Releases Results of 3-Year MiYOSMART Spectacle Lens Follow-up Studyhttps://modernod.com/news/hoya-vision-care-releases-results-of-3-year-miyosmart-spectacle-lens-follow-up-study/2479124/Hoya Vision Care shared the results of a 3-year follow-up clinical study on its MiYOSMART spectacle lens with patented Defocus Incorporated Multiple Segments (D.I.M.S.) Technology after releasing the information at the recent European Academy of Optometry and Optics (EAOO) ’21 conference. T